Global Hodgkin’s LymphomaTreatment Market Regional Analysis
North America is expected to holda dominant position in the global Hodgkin’sLymphoma Market over the forecast period. Frequent research and developmentactivities done by the government and other organizations is expected to drivethe North America Hodgkin’s lymphoma treatment market growth. For instance, inDecember 2016, Ohio State University Comprehensive Cancer Center and NationalCancer Institute (NCI) commenced a U.S. FDA clinical trial of Ibrutinib incombination with Nivolumab, in the patients suffering from classical Hodgkin’sLymphoma, in the U.S to study its efficacy. Ibritunib may block the cancer cellgrowth by blocking the enzymes responsible for growth and Nivolumab may blockcancer cells by targeting different cells. Currently, it’s in the second phaseof clinical trials. The study involves 17 participants and is estimated to becompleted by 2020.
Furthermore, various outsideorganizations are involved in research and development activities fordevelopment and gaining the U.S. FDA approval of novel Hodgkin’s lymphomatreatment drug in the U.S.
Lymphoma is a cancer caused inlymphocytes of the body, i.e. white blood cells. It is of two types – Hodgkin’sLymphoma and Non-Hodgkin’s Lymphoma. Hodgkin’s Lymphoma can be characterizedinto two categories – classic and nodular lymphocyte predominant. Some of thesigns indicating presence of Hodgkin’s Lymphoma in the body is fever, suddenweight loss, and swollen lymph nodes. Hodgkin’s Lymphoma is mostly treated withchemotherapy alone or with the combination of radiotherapy.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2658
Global Hodgkin’s LymphomaTreatment Market Drivers
Approvals of the drugs byregulatory bodies for the treatment of Hodgkin’s lymphoma is expected to drivethe global Hodgkin’s lymphoma market growth. In 2018, Seattle Genetics, Inc.received the Health Canada approval for its supplemental New Drug Submissionthat expands the use of Adcetris (brentuximab vedotin) in combination with AVD(Adriamycin, vinblastine and dacarbazine) chemotherapy in patients withpreviously untreated Stage IV Hodgkin lymphoma (HL). Adcetris is indicated forthe treatment of adult patients with previously untreated Stage III or IVclassical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine,and dacarbazine.
Furthermore, key players areconstantly trying to expand the indications of their already approved drug. Forinstance, in March 2017, Merck & Co. Inc. received an approval by U.S. Food& Drug Administration (FDA) of the drug, Keytruda for the treatment ofclassical Hodgkin’s lymphoma. It is approved on the basis of response durabilityand tumor response rate and is supposed to be administered intravenously intopatients. It was originally approved in 2014. Such frequent approvals of drugsby regulatory bodies are expected to impact positively on the global Hodgkin’slymphoma treatment market growth.
For instance, in September 2017,Chinese PLA General Hospital, a Chinese government organization, commenced itsclinical trial of Decitabine in combination with SHR – 1210. It is being usedfor the treatment of Hodgkin’s lymphoma. SHR – 1210 is a monoclonal antibody,while Decitabine is an investigational drug, which is capable of boostingantigen expression. The clinical study is for analyzing the safety and efficacyof the drugs. Currently, it is in the second phase of clinical trials.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/hodgkins-lymphoma-treatment-market-2658
Global Hodgkin’s LymphomaTreatment Market Restraints
Side effects related with drugsused for the treatment of Hodgkin’s lymphoma is expected to adversely affectadoption of these drugs, thereby hindering the global Hodgkin’s lymphomatreatment market growth. For instance, according to American Cancer Society,drugs used for treating Hodgkin’s lymphoma such as doxorubicin and bleomycincan damage heart and lungs respectively. Hence, such side effects of drugs canhinder the global Hodgkin’s lymphoma treatment market growth.
Global Hodgkin’s LymphomaTreatment Market Key Players
Some of the major playersoperating in the global Hodgkin’s lymphoma treatment market include EmcurePharmaceuticals Pvt. Ltd., Aspen Global Inc., Pfizer Inc., Ono PharmaceuticalsCo. Ltd., Corden Pharma Latina SPA, Horizon Pharma USA Inc., Cipla Ltd.,Lediant Biosciences Inc., Jansenn Research and Development LLC, and Merck &Co., Inc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2658
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related to emergingmarket trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
